Trajectory Analysis of Health Care Utilization Before and After Major Surgery.

Objective: To characterize patterns of health care utilization before and after surgery and determine any association with preoperative frailty.

Background: Frail patients experience worse postoperative outcomes and increased costs during the surgical encounter. Evidence is comparatively lacking for the longer-term effects of frailty on postoperative health care utilization.

Single-Dose Anti-Thymocyte Globulin Compared With Divided-Dose for Induction Therapy in Kidney Transplantation in a Predominantly Black Population.

Background: The aim of this study was to compare single-dose rabbit anti-thymocyte globulin (rATG) with a divided dose in kidney transplant recipients within a majority Black patient population.

Methods: We analyzed the outcomes before and after a change in protocol from divided-dose (1.5 mg/kg/day over 4 days) to single-dose (6 mg/kg over 24 hours) rATG in a retrospective cohort study.

Can Sanitation Technology Play a Role in User Perceptions of Resource Recovery? An Evaluation of Composting Latrine Use in Developing World Communities in Panama.

There remains a large unmet need for sanitation access throughout the world that compromises both human and environmental health. Opportunities exist to employ sanitation systems that better utilize and recover scarce resources from excreta such as water, energy, and nutrients. However, technologies such as a composting latrine may require more maintenance and close handling of feces compared to other sanitation technologies.

Netrin-1 Peptide Is a Chemorepellent in Tetrahymena thermophila.

Netrin-1 is a highly conserved, pleiotropic signaling molecule that can serve as a neuronal chemorepellent during vertebrate development. In vertebrates, chemorepellent signaling is mediated through the tyrosine kinase, src-1, and the tyrosine phosphatase, shp-2. Tetrahymena thermophila has been used as a model system for chemorepellent signaling because its avoidance response is easily characterized under a light microscope.

Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.

Purpose: Study distribution, pharmacokinetics, and safety of intraperitoneal (IP) 212Pb-TCMC-trastuzumab in patients with HER-2-expressing malignancy.

Experimental Design: IP 212Pb-TCMC-trastuzumab was delivered, after 4 mg/kg intravenous (IV) trastuzumab, to 3 patients with HER-2-expressing cancer who had failed standard therapies. Patients were monitored for toxicity and pharmacokinetics/dosimetry parameters.